Femasys

FEMY · NASDAQ

$1.67+$0.04 (+2.45%)TodayMarket closed · Oct 20, 7:24 PM ET

Prev close $1.63

FEMY analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $14.62 (+775.4% upside)

Low: $10.10
Now: $1.67
High: $24.15

Upgrades and downgrades

The latest rating actions, newest first

FEMY analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Lake Street	Aug 18, 2026	Maintains	Buy	$30.00 → $10.00	33%
Maxim Group	Aug 14, 2026	Maintains	Buy	$30.00 → $10.00	27%
Lake Street	Mar 3, 2026	Initiates	Buy	$1.50	33%
Laidlaw & Co.	Nov 20, 2025	Initiates	Buy	$6.50	7%

The case for and against

Updated Dec 15, 2025

Bull case

Femasys Inc. is positioned favorably for future growth due to its strong relationships with existing distributors, who have expressed willingness to expand partnerships for the commercialization of FemBloc. The familiarity of customers with the Femasys brand, stemming from their current offerings such as FemaSeed, enhances sales prospects as these distributors will leverage their established networks to drive demand. Additionally, Femasys could start recognizing revenue from FemBloc in the European market as early as the second half of 2025 or the first half of 2026, which represents a significant opportunity for the company’s expansion and overall financial performance.

Bear case

Femasys Inc faces significant risks that contribute to a negative outlook, primarily due to the potential for safety signals to emerge from its clinical or preclinical programs, which could jeopardize its product offerings. Additionally, concerns regarding the efficacy of its clinical programs not meeting expectations and greater-than-anticipated competition in the market could hinder the company's growth potential. Financial challenges are also notable, as the company may require approximately $60 million in additional financing to sustain its operations into 2038, further complicating its prospects for stability and expansion.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.